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This report presents findings from key informant interviews that were conducted to understand 
Hawaii prenatal providers’ use of screening, brief intervention, and referral to treatment (SBIRT) in 
everyday practice. Five prenatal providers who practice in Hawaii participated in the interviews. 
Although participants acknowledged the importance of utilizing SBIRT in prenatal care, SBIRT 
appeared to be underutilized. Most did not have standard SBIRT procedures incorporated within 
their practice. Participants’ primary concerns regarding routine use of SBIRT included time 
constraints, lack of technology within the electronic health record, and stigma. Recommendations 
from prenatal providers regarding SBIRT decision-making, billing process improvements, and 
provider incentives to enhance reimbursement practices are discussed.  
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To achieve a goal of healthier families and communities described in the Hawaii Governor’s 
State Health Innovation Plan, Hawaii MedQUEST Division (MQD) has engaged in a pilot project 
since November 2016 to reimburse prenatal care providers for screening, brief intervention, and 
referral to treatment (SBIRT). The pilot program allows Medicaid contracted prenatal providers 
(e.g., obstetricians, midwives) to complete designated SBIRT training and receive reimbursement, 
separate from prenatal care, for SBIRT interventions addressing alcohol, drug, and/or tobacco 
misuse. The pilot program excludes providers practicing in federally qualified health centers. 
Researchers conducted key informant interviews to understand prenatal providers’ utilization 
of SBIRT, to understand billing practices, and to also solicit suggestions for incentives that would 
increase providers’ submission of SBIRT claims. Overall findings were intended to inform key 
stakeholders of opportunities for process refinements and of possible incentives to support 




Interviews were conducted with five prenatal providers who practiced in Hawaii. 
Participants represented obstetrics and midwifery backgrounds and provided care in urban and rural 
settings across three islands as part of high-risk clinics, academic group practices, and private 
individual and group practices.  
Interviews 
A semi-structured interview guide was developed by the authors with input from MQD and 
members from the Hawaii Maternal and Infant Health Collaborative. Questions regarding SBIRT 
decision-making, delivery, and billing practices were asked, as well as prompts to solicit suggestions 
for billing process improvements and provider incentives to enhance reimbursement practices.  
Procedure 
A total of 119 potential participants were initially contacted via email and invited to 
participate in a brief interview. Invitations explaining the purpose of the interviews and participation 
information were sent through listervs of partner groups and by key stakeholders. Reminder emails 
were sent to MQD-specific SBIRT trainees and known contacts (n=23) identified by a stakeholder 
key informant. Of those who received reminder emails, 19 individuals also received a reminder 
phone call. 
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Telephone interviews were conducted by a trained doctoral student research assistant and 
lasted approximately 25 minutes. All interviews used the same procedures and were digitally 
recorded for transcription. Informed consent was verbally presented, reviewed, and agreed upon 
prior to beginning each interview.  
The procedure and interview guide were approved by the University of Alaska Anchorage’s 
Institutional Review Board. 
Analysis 
 Digital audio recordings were professionally transcribed then reviewed and edited for 
accuracy. A list of key domains, guided by the overall evaluation questions, was established by the 
research team members. Interviews were then summarized by domain and compiled into a matrix 
that was cross-checked by a second research team member. Discrepancies were flagged and 
discussed among the research team. The matrix was used to identify relationships and patterns in the 
data summaries. Transcripts were also imported into NVivo software for data coding whereby 
emergent relationships and patterns were verified to test and confirm conclusions.1 
Findings 
  
The following summary of findings are grouped into four distinct categories which are described in 
detail below: SBIRT Utilization, SBIRT Billing Practices, Incentives, and Overall Feedback.  
SBIRT Utilization 
Participants recognized a need for SBIRT in their practices, regardless of practice location or 
patient type. Screening was noted to occur when gathering a patient’s initial medical history and 
participants described different approaches to both identify and to manage positive cases. Very few 
were formally trained in SBIRT or other evidence-supported methods used to systematically identify 
at-risk alcohol or other substance use, and most expressed limited familiarity with SBIRT techniques 
(e.g., brief intervention, motivational interviewing). Those who were formally trained either had a 
personal interest in the issue or did so as preparation for grant-funded opportunities. 
                                                          
1 Miles, M. B., Huberman, A. M., & Saldana, J. (2014). Qualitative Data Analysis: A Methods Sourcebook (3rd 
Edition). Thousand Oaks, CA: Sage. 
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Time constraints, lack of follow-up resources, and stigma were primary concerns about 
routinely using SBIRT. One rural provider described being apprehensive to identify at-risk patients 
because of colleagues who preferred to “get them out of here and go somewhere else.” 
SBIRT Decision-Making. To understand when participants used SBIRT in prenatal care, 
several questions regarding decision-making were asked. Participants described screening for all 
substance use, including alcohol and tobacco, as part of general prenatal visits, prenatal 
consultations, women’s health visits, and family planning visits. The frequency of SBIRT use was 
estimated to range from “every visit” to only initial visits or to “those I’m concerned about”, and 
depended on practice environments. One provider who used a structured approach described:  
I'll definitely talk about it with them on their first visit, and then if they screen positive, 
we address it almost every visit... Towards the end of the pregnancy they're coming in 
every week, so I might not discuss it every week, you know, if they just talked about it the 
previous week. But certainly in the beginning, we'll talk about it at every visit.  
Others screened infrequently; reasons included lack of “concrete” protocols or basing decisions on 
perceived patient needs. One participant explained, “if there is no disclosure to drug or substance 
abuse [during the initial visit], then we just look for signs that we might see as we continue prenatal 
care.” Additionally, some providers, particularly those in more rural settings, believed that they knew 
patients’ substance use behaviors and therefore did not see the need to screen at every visit. One 
participant shared, “...sometimes I know by word of mouth that someone has a drug problem. So 
[the patient] might not tell me right away, but I'll already know.” 
Electronic medical records (EMR) played a role in SBIRT decision-making and subsequent 
utilization. One participant described: 
I wouldn’t say it's a policy, but I would say that it's a standard practice, and it probably 
has to do partially with our EMR...There are spaces where that information needs to be 
inputted into the prenatal record, and so we try to fill it out as completely as possible at 
the patient's first visit. 
Other participants worked in clinics where SBIRT utilization was up to the individual provider 
including one participant who stated SBIRT was likely “ignored” because it “has not been built into 
the EMR and it’s not a requirement.” 
Very few participants reported using a validated screening instrument. Most relied on open-
ended questions or “an open-ended history” approach with new patients or throughout care. Of 
those who did use an instrument, the T-ACE and 4Ps Plus were provided as specific screening tools. 
Lack of physician training, time restrictions, and limited EMR capabilities were barriers to routine 
screening. 
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All participants stated that financial compensation had little to no influence on whether or 
not to use SBIRT in prenatal care. For those who routinely screened, reimbursement had no impact. 
One participant shared, “Billing is not a motivation for me to do it, and it’s also not a hindrance 
either.” Another acknowledged reimbursement provided “something for the effort” but described 
that reimbursement was not a strong factor for doing it since “you get so little for it.”  
Delivery. Most participants indicated that they and their clinical settings did not have standard 
SBIRT procedures. All preferred to screen and deliver brief interventions themselves in order to 
follow indicated patients; as explained by one participant, “...so that we can talk about the effects on 
their pregnancy and discuss whether they're interested in either quitting or getting a referral for 
treatment.” Many conveyed a need for assistance to coordinate referrals while some preferred to 
contact specialists personally when a referral was indicated. 
Participants differed in their descriptions of addressing positive cases. For example, one 
participant who screened at every visit shared, “...patients who are using substances will get short 
counseling during their visit, depending on whether or not they're interested in that at the time.” 
Others only described a positive response to substance use inquiry was documented as part of the 
initial visit, with no description of any type of procedure to address the issue at that visit or monitor 
in the future. Additionally, some participants addressed only positive tobacco use and not alcohol or 
other substances. When it was described, follow-up and monitoring ranged from occurring at nearly 
every visit to sporadically throughout care; however, a majority patients who screened positive for 
substances other than tobacco were described as being referred to an outside provider or specialist. 
No participants mentioned working in an integrated care setting or having any type of in-house 
referral sources. 
Impact. Some participants perceived that SBIRT was “fairly effective” for addressing risky 
alcohol use among their patients while others expressed some degree of uncertainty towards the 
effectiveness of SBIRT. Outside of improving challenges of time constraints or lack of support to 
coordinate care, participants were unable to identify ways to improve SBIRT effectiveness. One 
participant explained, “That's probably our fault that we're not really doing it and it’s simply because 
of the level of training and also the lack of support in order to make it happen.” 
When asked about potential impacts SBIRT has had on their prenatal practice, some 
participants stated that SBIRT has had “a positive impact”, including one participant who reflected, 
“I think if anything, it's just a big awareness.” Others indicated SBIRT had little impact beyond 
increased personal awareness of community resources for substance use. One participant explained, 
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“...otherwise, even before SBIRT was being discussed, we did talk about those things with prenatal 
patients so I don't feel like it's increased my screenings necessarily.” However, standard SBIRT 
procedures made participants more comfortable in their provider role and reduced stigma; one 
provider shared that universal screening ensures patients “don’t feel like they’re being picked on.” 
Standardizing SBIRT also seemed to impact provider assumptions; participants shared that positive 
cases were not necessarily among the patients that providers would have anticipated to screen 
positive. 
Finally, participants described promotion of awareness of various community resources as a 
positive impact of SBIRT. Similarly, the referral aspects of SBIRT promotes necessary partnerships 
to effectively address substance use during pregnancy. 
 
SBIRT Billing Practices 
Very few participants worked in practices where SBIRT claims were being submitted. Those 
that were billing described the reimbursement process as “straightforward” and “pretty simple to 
do.” One participant was billing under “counseling” but did not know what happened beyond 
entering the billing code. Some were unaware that SBIRT is a reimbursable service.  
A substantial obstacle to SBIRT billing was the absence of SBIRT within the “global 
prenatal outpatient care package,” highlighting the connection between packaged maternity care 
coding to a clinic’s electronic medical record software, and to the physician’s office billing system 
which may or may not be set up to code outside of the obstetric package. One participant explained 
their practice’s lack of SBIRT billing and described,  
I don't think we know how to do it. I don’t think there is a way to do it...so many things 
are directed by the electronic medical record, and if it's not easily accessible or built into 
the system...we tend to overlook it and move onto things that need to be addressed that 
are in the system or that is the main reason for the patient's referral. 
Time was another explicit barrier to billing. One participant explained that interventions can 




Providers were asked for their suggestions for incentives to potentially increase SBIRT 
utilization and billing within their medical specialty. Financial support to add and modify EMR 
processes specific for SBIRT was suggested, including the development of an embedded SBIRT 
checklist. “Some type of bonus” was encouraged. Participants described that continued advertising 
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about SBIRT reimbursement is needed; this advertising was encouraged to be “intense education”, 
structured as brief conversations with providers during a lunch hour, combined with offering food, 
and with the idea to “explain the whole SBIRT item and emphasize to doctors how they would go 
ahead and get reimbursement for it.”  
For some, incentives did not play a role in personal motivation to use SBIRT and they were 
therefore uncertain whether incentives would actually help to promote SBIRT utilization.  
 
Overall Feedback 
Participants gave a range of suggestions to improve SBIRT utilization in prenatal practice. 
First, they recommended that reimbursement guidelines allow a wider range of health care providers 
(e.g., social workers, mental health professionals) to receive compensation for SBIRT services in 
order to facilitate adoption. Second, participants indicated that it is important to streamline 
systematic processes for SBIRT administration and billing. Specifically, a participant suggested that 
depression screening could provide an appropriate model (i.e., medical assistant administers 
screening, physician looks at the result and determines follow-up and referral if necessary).  
The third recommendation was to strategically advertise SBIRT to prenatal providers. One 
participant suggested identifying the right person in each setting who is “most likely going to do it” 
and communicating information about SBIRT and the incentive: 
If it's the doctor, you would talk to the doctor. If it's the nurses or the HRN or if it's a 
physician's assistant or if it's the nurse or whatever, we would be talking to them, plus as far 
as the doctor. And then just keying in on the right people to go ahead. And as far as doing 
it...then saying well, for your efforts you're going to go ahead and get a monetary incentive. 
Fourth, participants suggested SBIRT training focused on communication skills, including 
how to appropriately ask and answer questions, is essential. In particular, participants recommended 
continuing education as necessary to increase knowledge about caring for pregnant women who use 
substances; required education was also proposed. Finally, the fifth recommendation was to foster 
relationships with referral sources as necessary for SBIRT to be completed consistently. One 
provider shared, "…the worst thing is to screen and then have somebody who is interested in 
treatment and not having a place to refer them to." 
  





Providers in Hawaii who participated in this evaluation recognized the important role of 
SBIRT in prenatal care; however, SBIRT appeared to be underutilized by the participants and in 
their practices. Financial compensation was not a strong motivator to do SBIRT and participants 
who were routinely using it described personal motivation to do so based on the clinical implications 
associated with prenatal alcohol exposure. Thus, continued SBIRT training tailored to prenatal care 
settings including education about the type of patients who are likely to benefit from SBIRT, as well 
as the nature of brief counseling and interventions, were viewed as important to support provider 
adoption.  
Integrated care settings were likely to facilitate routine SBIRT utilization. Ancillary staff and 
technical support at the workflow level could help to address prenatal providers’ barriers associated 
with time limitations and lack of training, as well as to optimize SBIRT capabilities within the EMR. 
Participants identified systems- and policy-level barriers to SBIRT billing. The interplay of 
established EMR software and maternity billing packages restricted several participants’ ability to do 
SBIRT and to bill for it. Some discussed how SBIRT billing is a separate and distinct code outside of 
the global obstetrics reimbursement schedule and, as such, added confusion about whether or not 
they could do SBIRT, including uncertainty whether office staff would be able to bill for it. On the 
other hand, participants who were actively billing for SBIRT described fairly simple procedures. 
These perspectives underscore the potential for strategic outreach by clinician champions to key 
stakeholders including providers, coders, and health system administrators, to promote SBIRT 
uptake and billing in prenatal care settings. Finally, policies allowing a broader range of healthcare 
providers (e.g., nurse-midwives, social workers, health educators) to receive reimbursement for 
SBIRT may also enhance utilization in obstetrical care. 
